555 results on '"Folliculitis drug therapy"'
Search Results
2. Editor's Highlights - September 2024.
- Author
-
Kemény L
- Subjects
- Humans, Exosomes, Dermal Fillers adverse effects, Dermal Fillers administration & dosage, Folliculitis diagnosis, Folliculitis drug therapy, Hair growth & development, Hair drug effects, Hair Follicle, Adipose Tissue, Glucagon-Like Peptide 1 agonists, Alopecia therapy, Alopecia drug therapy, Alopecia diagnosis
- Abstract
Curly textured hair presents unique diagnostic and therapeutic challenges because of its distinct properties. In the September issue of the Journal, we explore recent advancements in understanding and treating various hair disorders, focusing on the specific challenges and treatments for curly hair. We discuss whether glucagon-like peptide-1 agonists contribute to or alleviate hair loss and highlight a promising, innovative therapy using adipose stem cell-derived exosomes to promote hair growth. Additionally, we examine therapeutic options for managing filler-induced alopecia and treating folliculitis decalvans., (© 2024 the International Society of Dermatology.)
- Published
- 2024
- Full Text
- View/download PDF
3. Scalp microbiome: a guide to better understanding scalp diseases and treatments.
- Author
-
Shah RR, Larrondo J, Dawson T, and Mcmichael A
- Subjects
- Humans, Scalp Dermatoses microbiology, Scalp Dermatoses drug therapy, Scalp Dermatoses therapy, Dysbiosis microbiology, Dysbiosis immunology, Folliculitis microbiology, Folliculitis diagnosis, Folliculitis drug therapy, Folliculitis therapy, Psoriasis microbiology, Psoriasis drug therapy, Psoriasis immunology, Psoriasis therapy, Dermatitis, Seborrheic microbiology, Dermatitis, Seborrheic drug therapy, Dermatitis, Seborrheic therapy, Alopecia Areata microbiology, Alopecia Areata immunology, Alopecia Areata therapy, Alopecia Areata drug therapy, Dandruff microbiology, Dandruff drug therapy, Microbiota drug effects, Microbiota immunology, Scalp microbiology
- Abstract
The scalp microbiome represents an array of microorganisms important in maintaining scalp homeostasis and mediating inflammation. Scalp microbial dysregulation has been implicated in dermatologic conditions including alopecia areata (AA), dandruff/seborrheic dermatitis (D/SD), scalp psoriasis (SP) and folliculitis decalvans (FD). Understanding the impact of scalp microbial dysbiosis gives insight on disease pathophysiology and guides therapeutic decision making. Herein we review the scalp microbiome and its functional role in scalp conditions by analysis of metagenomic medical literature in alopecia, D/SD, SP, and other dermatologic disease.Increased abundance of Malassezia, Staphylococcus, and Brevibacterium was associated with SD compared to healthy controls. A higher proportion of Corynebacterium, actinobacteria, and firmicutes are present in AA patients, and lower proportions of Staphylococcus caprae are associated with worse clinical outcomes. Decreased prevalence of actinobacteria and Propionibacterium and increased firmicutes, staphylococcus, and streptococcus are associated with scalp psoriasis. Studies of central centrifugal cicatricial alopecia (CCCA) suggest scalp microbial composition contributes to CCCA's pro-inflammatory status. The most common organisms associated with FD include methicillin-resistant S. aureus and S. lugdunensis. Antifungals have been a mainstay treatment for these diseases, while other alternatives including coconut oils and shampoos with heat-killed probiotics have shown considerable potential efficacy by replenishing the scalp microbiome., (© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)
- Published
- 2024
- Full Text
- View/download PDF
4. Cold atmospheric plasma therapy for Malassezia folliculitis: Laboratory investigations and a randomized clinical trial.
- Author
-
Wang N, Yan T, Mei X, Liu J, Lei Y, and Yang C
- Subjects
- Humans, Adult, Female, Male, Middle Aged, Itraconazole therapeutic use, Itraconazole pharmacology, Young Adult, Treatment Outcome, Biofilms drug effects, Malassezia drug effects, Folliculitis drug therapy, Folliculitis microbiology, Plasma Gases pharmacology, Plasma Gases therapeutic use, Antifungal Agents pharmacology, Antifungal Agents therapeutic use, Dermatomycoses drug therapy, Dermatomycoses microbiology
- Abstract
Background: Current treatment options for Malassezia folliculitis (MF) are limited. Recent research has demonstrated the inhibitory effect of cold atmospheric plasma (CAP) on the growth of Malassezia pachydermatis in vitro, suggesting CAP as a potential therapeutic approach for managing MF., Objectives: The objective of our study is to assess the in vitro antifungal susceptibility of Malassezia yeasts to CAP. Additionally, we aim to evaluate the efficacy and tolerability of CAP in treating patients with MF., Methods: We initially studied the antifungal effect of CAP on planktonic and biofilm forms of Malassezia yeasts, using well-established techniques such as zone of inhibition, transmission electron microscopy, colony count assay and 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide salt assay. Subsequently, a randomized (1:1 ratio), active comparator-controlled, observer-blind study was conducted comparing daily CAP therapy versus itraconazole 200 mg/day for 2 weeks in 50 patients with MF. Efficacy outcomes were measured by success rate, negative microscopy rate and changes in Dermatology Life Quality Index (DLQI) and Global Aesthetic Improvement Scale (GAIS) scores. Safety was assessed by monitoring adverse events (AEs) and local tolerability., Results: In laboratory investigations, CAP time-dependently inhibited the growth of Malassezia yeasts in both planktonic and biofilm forms. Forty-nine patients completed the clinical study. At week 2, success was achieved by 40.0% of subjects in the CAP group versus 58.3% in the itraconazole group (p = 0.199). The negative direct microscopy rates of follicular samples were 56.0% in the CAP group versus 66.7% in the itraconazole group (p = 0.444). No significant differences were found in the proportion of subjects achieving DLQI scores of 0/1 (p = 0.456) or in the GAIS responder rates (p = 0.588) between the two groups. Three patients in the CAP group and one patient in the itraconazole group reported mild AEs., Conclusion: CAP demonstrated significant antifungal activity against Malassezia yeasts in vitro and exhibited comparable efficacy to itraconazole in treating MF patients. Without the associated adverse effects of oral antifungal drugs, CAP can be considered a promising and safe treatment modality for MF., (© 2024 The Author(s). Skin Research and Technology published by John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
5. A case of generalized eosinophilic pustular folliculitis: treatment with JAK inhibitor.
- Author
-
Zheng C, Yu Y, Zhou G, and Liu H
- Subjects
- Humans, Adolescent, Janus Kinase Inhibitors therapeutic use, Folliculitis drug therapy, Eosinophilia drug therapy, Skin Diseases, Vesiculobullous drug therapy
- Abstract
Aim: This case study aims to report the efficacy and safety of a Janus kinase (JAK) inhibitor in the treatment of generalized eosinophilic pustular folliculitis (EPF)., Methods: We present a case of a 16-year-old Chinese patient who had been suffering from EPF for two years and had shown no response to both topical and systemic glucocorticoids. The patient was subsequently treated with oral tofacitinib at a dosage of 5mg daily., Results: Significant remission of eruption and pruritus was observed in the patient upon treatment with tofacitinib. However, a relapse occurred upon dose reduction. Subsequent switch to the highly selective JAK1 inhibitor upadacitinib resulted in complete recovery, with the patient achieving a symptom-free status after six months., Conclusions: JAK inhibitors show promise as a potential treatment option for EPF patients who do not respond to traditional therapies.
- Published
- 2024
- Full Text
- View/download PDF
6. Common Skin Conditions in Children and Adolescents: Bacterial Infections.
- Author
-
Zha M and Usatine R
- Subjects
- Humans, Child, Adolescent, Folliculitis diagnosis, Folliculitis drug therapy, Folliculitis microbiology, Erysipelas diagnosis, Erysipelas drug therapy, Abscess diagnosis, Abscess therapy, Abscess microbiology, Furunculosis diagnosis, Furunculosis drug therapy, Furunculosis therapy, Furunculosis microbiology, Carbuncle diagnosis, Carbuncle therapy, Anti-Bacterial Agents therapeutic use, Impetigo diagnosis, Impetigo drug therapy, Skin Diseases, Bacterial diagnosis, Skin Diseases, Bacterial drug therapy, Skin Diseases, Bacterial microbiology, Skin Diseases, Bacterial therapy, Cellulitis diagnosis, Cellulitis drug therapy, Cellulitis microbiology, Cellulitis therapy
- Abstract
Bacterial skin infections represent a significant health care burden. Cellulitis and erysipelas are rapidly spreading, painful, superficial skin infections, usually caused by streptococci or Staphylococcus aureus . Folliculitis is an infection of hair follicles mostly caused by S aureus . Simple folliculitis typically is self-limited. Topical benzoyl peroxide is a first-line nonantibiotic treatment. Mupirocin and clindamycin are topical antibiotic options. For treatment-resistant cases, oral cephalexin or dicloxacillin is an appropriate option. Impetigo is a common, self-limited infection in children. Bullous impetigo is caused by S aureus , and nonbullous impetigo is caused by beta-hemolytic streptococci, S aureus , or both. In most cases, topical mupirocin or retapamulin (Altabax) is effective. Oral antibiotics should be considered for household outbreaks or patients with multiple lesions. Abscesses are red, painful collections of purulence in the dermis and deeper tissues caused by S aureus or polymicrobial infections. Furuncles are abscesses of a hair follicle, whereas carbuncles involve several hair follicles. In recurrent cases of these lesions, culture of the exudate is recommended. Abscess, furuncle, and carbuncle management consists of incision and drainage. Oral antibiotics are not necessary in most cases but should be prescribed for patients with severe immunocompromise or systemic signs of infection. In bacterial skin infections, methicillin-resistant S aureus coverage should be considered for patients with infections that have not improved with treatment., (Written permission from the American Academy of Family Physicians is required for reproduction of this material in whole or in part in any form or medium.)
- Published
- 2024
7. Recalcitrant Folliculitis Decalvans Treatment Outcomes With Biologics and Small Molecule Inhibitors.
- Author
-
Fakhoury T, Urban K, Ettefagh L, and Nami N
- Subjects
- Humans, Janus Kinase Inhibitors therapeutic use, Antibodies, Monoclonal therapeutic use, Antibodies, Monoclonal pharmacology, Alopecia drug therapy, Treatment Outcome, Folliculitis drug therapy, Biological Products therapeutic use, Phosphodiesterase 4 Inhibitors therapeutic use
- Abstract
Folliculitis decalvans (FD) is a rare primary neutrophilic cicatricial alopecia that commonly displays resistance to traditional therapies and remains challenging to treat. Currently, data are lacking with recommendations for therapy-recalcitrant FD. A systematic review was conducted to analyze biologics, small molecule inhibitors, tumor necrosis factor (TNF) inhibitors, Janus kinase (JAK) inhibitors, phosphodiesterase 4 (PDE4) inhibitors, and monoclonal antibodies utilized in the treatment of recalcitrant FD.
- Published
- 2024
- Full Text
- View/download PDF
8. Recalcitrant folliculitis decalvans successfully controlled with adalimumab.
- Author
-
Ramos J, Silva AM, António AM, and Alves J
- Subjects
- Humans, Treatment Outcome, Scalp Dermatoses drug therapy, Scalp Dermatoses pathology, Anti-Inflammatory Agents therapeutic use, Female, Male, Adult, Adalimumab therapeutic use, Folliculitis drug therapy, Folliculitis pathology
- Published
- 2024
- Full Text
- View/download PDF
9. Clinical Characterization and Treatment Response of Folliculitis Decalvans Lichen Planopilaris Phenotypic Spectrum: A Unicentre Retrospective Series of 31 Patients.
- Author
-
Melián-Olivera A, Moreno-Arrones Ó, Burgos-Blasco P, Hermosa-Gelbard Á, Jaén-Olasolo P, Vañó-Galván S, and Saceda-Corralo D
- Subjects
- Female, Humans, Alopecia diagnosis, Alopecia drug therapy, Alopecia pathology, Cicatrix, Retrospective Studies, Steroids, Folliculitis diagnosis, Folliculitis drug therapy, Lichen Planus complications, Lichen Planus diagnosis, Lichen Planus drug therapy
- Abstract
Folliculitis decalvans and lichen planopilaris phenotypic spectrum has been described as a form of cicatricial alopecia. The aim of this study is to describe the clinical and trichoscopic features and therapeutic management of this condition in a series of patients. A retrospective observational unicentre study was designed including patients with folliculitis decalvans and lichen planopilaris phenotypic spectrum confirmed with biopsy. A total of 31 patients (20 females) were included. The most common presentation was an isolated plaque of alopecia (61.3%) in the vertex. Trichoscopy revealed hair tufting with perifollicular white scaling in all cases. The duration of the condition was the only factor associated with large plaques (grade III) of alopecia (p = 0.026). The mean time to transition from the classic presentation of folliculitis decalvans to folliculitis decalvans and lichen planopilaris phenotypic spectrum was 5.2 years. The most frequently used treatments were topical steroids (80.6%), intralesional steroids (64.5%) and topical antibiotics (32.3%). Nine clinical relapses were detected after a mean time of 18 months (range 12-23 months). Folliculitis decalvans and lichen planopilaris phenotypic spectrum is an infrequent, but probably underdiagnosed, cicatricial alopecia. Treatment with anti-inflammatory drugs used for lichen planopilaris may be an adequate approach.
- Published
- 2024
- Full Text
- View/download PDF
10. Two cases of infancy associated eosinophilic pustular folliculitis (I-EPF) comparing the profile of infiltrating cells with classic EPF by immunohistochemical study.
- Author
-
Takei S, Hayashi R, Tomii K, Deguchi T, Fujikawa H, Shinkuma S, and Abe R
- Subjects
- Humans, Indomethacin therapeutic use, Eosinophilia drug therapy, Eosinophilia pathology, Folliculitis drug therapy, Folliculitis pathology, Skin Diseases, Vesiculobullous drug therapy, Skin Diseases, Vesiculobullous pathology
- Abstract
Infancy associated eosinophilic pustular folliculitis (I-EPF) is a clinical variant of EPF that develops in childhood. Previous studies have suggested that I-EPF exhibits clinical and histological differences distinct from other variants, including classic EPF. Herein, we report two patients with I-EPF treated with topical indomethacin. These two cases exhibited less perifollicular and more perivascular eosinophilic infiltration, which is different in distribution from that of classic EPF. Immunohistochemical study demonstrated that the infiltrating mononuclear cells were CD4-dominant T cells in classic EPF and I-EPF, whereas the number of CD68-positive cells was significantly higher in classic EPF than in I-EPF. Immunohistochemical staining was also performed for eosinophilic pustular folliculitis (HPGDS), which has been reported to induce eosinophils and is a therapeutic target of indomethacin in classic EPF. HPGDS-positive cells were also observed in I-EPF, which may explain the effectiveness of topical indomethacin. Although clinical and histopathological features of I-EPF are different from other variants, the arachidonic acid pathway could be involved in eosinophil infiltration, not only in classic EPF but also in I-EPF., (© 2023 Japanese Dermatological Association.)
- Published
- 2024
- Full Text
- View/download PDF
11. Successful Treatment of Eosinophilic Pustular Folliculitis With Dupilumab.
- Author
-
Ottavi M, Velin M, Cardot Leccia N, and Passeron T
- Subjects
- Humans, Eosinophilia diagnosis, Eosinophilia drug therapy, Folliculitis diagnosis, Folliculitis drug therapy, Skin Diseases, Vesiculobullous diagnosis, Skin Diseases, Vesiculobullous drug therapy, Antibodies, Monoclonal, Humanized
- Published
- 2024
- Full Text
- View/download PDF
12. Diagnostic delay, comorbid hidradenitis suppurativa and the prognostic value of bacterial culture in folliculitis decalvans: A cohort study.
- Author
-
Lyakhovitsky A, Segal O, Galili E, Thompson CT, Tzanani I, Scope A, Baum S, and Barzilai A
- Subjects
- Humans, Cohort Studies, Delayed Diagnosis, Prognosis, Retrospective Studies, Staphylococcus aureus, Alopecia diagnosis, Alopecia epidemiology, Alopecia drug therapy, Hidradenitis Suppurativa diagnosis, Hidradenitis Suppurativa epidemiology, Hidradenitis Suppurativa complications, Folliculitis diagnosis, Folliculitis epidemiology, Folliculitis drug therapy
- Abstract
Background: Folliculitis decalvans (FD) is a type of primary neutrophilic cicatricial alopecia often leading to irreversible hair loss. Data on its epidemiology, clinical features, outcomes, and prognostic factors are limited., Objective: To evaluate a cohort of patients with FD and identify characteristics of severe disease and prognostic factors which impede remission., Patients and Methods: This retrospective cohort study included 192 patients diagnosed with FD and followed for at least six months at a tertiary center between 2010 and 2020., Results: There was a diagnostic delay averaging 22.2 (± 29.7) months. Comorbid follicular occlusion disorders were common. Bacterial cultures were positive in 45.6% of the cases, with Staphylococcus (S.) aureus being the most common pathogen. Severe disease was associated with comorbid hidradenitis suppurativa and a positive bacterial culture, particularly S. aureus. 50.7% of patients experienced complete remission: 32% within the first six months of treatment and 18.7% later during follow-up. Relapses were frequent. Negative prognostic factors for achieving remission included younger age and a positive bacterial culture., Conclusions: There is a need for the education of dermatologists to reduce the diagnostic delay. Screening FD patients for comorbid hidradenitis suppurativa and obtaining bacterial cultures is important for treatment planning., (© 2023 Deutsche Dermatologische Gesellschaft (DDG).)
- Published
- 2023
- Full Text
- View/download PDF
13. Iatrogenic Demodex folliculitis: A case report.
- Author
-
Deo N, Isaq NA, Peters MS, and Link J
- Subjects
- Humans, Animals, Female, Middle Aged, Skin pathology, Iatrogenic Disease, Mite Infestations diagnosis, Mite Infestations drug therapy, Mite Infestations complications, Folliculitis diagnosis, Folliculitis drug therapy, Folliculitis etiology, Mites
- Abstract
Demodex folliculorum is a commensal mite that inhabits the orifices of cutaneous pilosebaceous follicles. Overgrowth of these organisms can lead to Demodex folliculitis, which typically presents as papules and pustules predominantly involving the temples, cheeks, and occasionally the chest. We present a 51-year-old woman with iatrogenic Demodex folliculitis secondary to immunosuppressive treatment for an autoimmune connective tissue disease. Histopathological exam of a skin biopsy, which revealed follicular Demodex mites, confirmed the diagnosis. The eruption was treated with oral ivermectin and topical metronidazole gel, and the patient's immunosuppressive regimen was decreased, resulting in marked improvement in the eruption within 6 weeks and no worsening of her underlying autoimmune disorder. This case emphasizes the importance of considering Demodex folliculitis in the differential diagnosis of a new onset rash in the context of immunosuppressive treatment., (© 2023 Asia Pacific League of Associations for Rheumatology and John Wiley & Sons Australia, Ltd.)
- Published
- 2023
- Full Text
- View/download PDF
14. A case of pemphigus vulgaris with folliculitis-like nodules, genital and oral ulcers difficult to differentiate from Behçet's disease.
- Author
-
Yamaoka T, Takahashi S, Ijuin K, Nagai H, and Kumagai S
- Subjects
- Humans, Genitalia, Oral Ulcer diagnosis, Oral Ulcer drug therapy, Oral Ulcer etiology, Behcet Syndrome complications, Behcet Syndrome diagnosis, Behcet Syndrome drug therapy, Pemphigus diagnosis, Pemphigus drug therapy, Folliculitis diagnosis, Folliculitis drug therapy, Folliculitis etiology
- Published
- 2023
- Full Text
- View/download PDF
15. EGFR inhibitor-induced folliculitis decalvans: a case series and management guidelines.
- Author
-
Nowaczyk J, Fret K, Kaminska-Winciorek G, Rudnicka L, and Czuwara J
- Subjects
- Humans, Female, Quality of Life, ErbB Receptors, Alopecia chemically induced, Alopecia drug therapy, Folliculitis chemically induced, Folliculitis complications, Folliculitis drug therapy, Carcinoma, Non-Small-Cell Lung drug therapy, Lung Neoplasms drug therapy, Lung Neoplasms complications
- Abstract
Epidermal growth factor receptor (EGFR) is one of therapeutic targets in oncology for solid tumors originating from epithelial tissue, such as non-small-cell lung carcinoma (NSCLC) and breast cancer. EGFR inhibitors used in cancer treatment may cause a broad spectrum of dose-dependent cutaneous adverse events, including acneiform papulopustular rash, nail and hair disturbances, xerosis, and mucositis. The pathogenesis of the EGFR inhibitor-induced adverse reactions originates from disturbances in keratinocyte differentiation, cytokine secretion, and neutrophil chemotaxis. One of the rare, yet distressing adverse events may be folliculitis decalvans, a progressive neutrophil-driven scarring alopecia with hair tufts formation resembling doll's hair. Early diagnosis and introduction of treatment are crucial for disease prognosis since a long course of the disease leads to decreased quality of life. Here, we review the literature cases of EGFR inhibitor-induced folliculitis decalvans and provide guidance on management and prevention of this condition in oncologic patients. Furthermore, we report the first afatinib-associated folliculitis decalvans in three female patients with NSCLC., (Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc.)
- Published
- 2023
- Full Text
- View/download PDF
16. Clinical characteristics and treatment outcomes of Pityrosporum folliculitis in immunocompetent patients.
- Author
-
Green M, Feschuk AM, Kashetsky N, and Maibach HI
- Subjects
- Humans, Male, Female, Young Adult, Adult, Antifungal Agents therapeutic use, Pruritus drug therapy, Treatment Outcome, Malassezia, Dermatomycoses diagnosis, Dermatomycoses drug therapy, Dermatomycoses microbiology, Folliculitis diagnosis, Folliculitis drug therapy, Acne Vulgaris diagnosis, Acne Vulgaris drug therapy, Acne Vulgaris microbiology
- Abstract
Pityrosporum folliculitis (PF) is a fungal acneiform disease of the hair follicles that often presents with pruritic papules and pustules on the upper body and face
. This condition is commonly mistaken for acne vulgaris and can be distinguished from bacterial acne by the presence of fungal spores in the follicular lumen. Although studies have been performed to describe PF in cohorts, little work has been done to aggregate these data. Thus, the goal of this review is to describe the clinical characteristics and treatment outcomes of PF in immunocompetent patients. PubMed, Web of Science, and Embase were searched using the terms "Pityrosporum folliculitis" or "Malassezia folliculitis." All cohorts reporting PF characteristics in patients classified as immunocompetent were reviewed. A total of 15 studies were included. Majority of patients were male (64%) with the average age of presentation of 24.26 years. The most common locations of lesions were the chest (70%) and back/shoulders (69.2%). Pruritus was reported by the majority of patients (71.7%). Additionally, 40.5% of patients reported a history of unsuccessful treatment regimens. Treatment was most successful with an oral antifungal (92%), followed by a topical antifungal (81.6%). In conclusion, majority of patients with PF were younger males. Many patients were primarily treated incorrectly, suggesting the importance of proper diagnosis. PF may be distinguishable from acne vulgaris by the presence of pruritus or suggested when a new acneiform eruption develops following antibiotic therapy or immunosuppression. When properly diagnosed, majority of cases of PF achieve complete response with oral or topical antifungals., (© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)- Published
- 2023
- Full Text
- View/download PDF
17. Position statement: Recommendations on the diagnosis and treatment of Malassezia folliculitis.
- Author
-
Henning MAS, Hay R, Rodriguez-Cerdeira C, Szepietowski JC, Piraccini BM, Ferreirós MP, Arabatzis M, Sergeev A, Nenoff P, Kotrekhova L, Nowicki RJ, Faergemann J, Padovese V, Prohic A, Skerlev M, Schmid-Grendelmeier P, Sigurgeirsson B, Gaitanis G, Lecerf P, and Saunte DML
- Subjects
- Humans, Malassezia, Dermatomycoses diagnosis, Folliculitis drug therapy
- Abstract
Malassezia is a lipophilic yeast that is a part of the human mycobiome. Malassezia folliculitis appears when the benign colonization of the hair follicles, by the Malassezia yeasts, becomes symptomatic with pruritic papules and pustules. Although Malassezia folliculitis is common in hospital departments, diagnosing and treating it varies among dermatologists and countries. The European Academy of Dermatology and Venereology Mycology Task Force Malassezia folliculitis working group has, therefore, sought to develop these recommendations for the diagnosis and management of Malassezia folliculitis. Recommendations comprise methods for diagnosing Malassezia folliculitis, required positive findings before starting therapies and specific treatment algorithms for individuals who are immunocompetent, immunocompromised or who have compromised liver function. In conclusion, this study provides a clinical strategy for diagnosing and managing Malassezia folliculitis., (© 2023 European Academy of Dermatology and Venereology.)
- Published
- 2023
- Full Text
- View/download PDF
18. A Case of Eosinophilic Pustular Folliculitis with Vegetating Lesions on the Lower Legs and Feet Resembling Pemphigus Vegetans.
- Author
-
Kakurai M, Oya K, Furuta J, Iijima S, and Nomura T
- Subjects
- Humans, Leg pathology, Pemphigus diagnosis, Pemphigus drug therapy, Pemphigus pathology, Skin Diseases, Vesiculobullous diagnosis, Skin Diseases, Vesiculobullous drug therapy, Eosinophilia diagnosis, Eosinophilia drug therapy, Folliculitis diagnosis, Folliculitis drug therapy
- Published
- 2023
- Full Text
- View/download PDF
19. Efficacy and Safety of Tumour Necrosis Factor-α Antagonists for Folliculitis Decalvans: A Retrospective Case-series Pilot Study.
- Author
-
Dupont A, Eyraud A, Milpied B, De Bataille S, Cassassa E, Darrigade AS, Barnetche T, Doutre MS, Matard B, Beylot-Barry M, and Seneschal J
- Subjects
- Humans, Pilot Projects, Retrospective Studies, Alopecia etiology, Necrosis complications, Immunoglobulin A, Tumor Necrosis Factor Inhibitors therapeutic use, Folliculitis diagnosis, Folliculitis drug therapy, Folliculitis pathology
- Abstract
Folliculitis decalvans is a chronic inflammatory skin disease leading to scarring alopecia. Management of this disabling disease is difficult and no treatment is currently approved. Current knowledge regarding the pathogenesis of folliculitis decalvans suggests the benefit of using anti-tumour necrosis factor-α. This pilot study aimed to evaluate the clinical efficacy of anti-tumour necrosis factor-α for management of folliculitis decalvans. A single-centre retrospective pilot study included patients with refractory folliculitis decalvans treated by tumour necrosis factor-α inhibitors. An Investigator's Global Assessment (IGA) score was designed and validated to assess the efficacy of the therapy. Response to treatment was considered good to excellent when an IGA ≤ 2 was obtained at month 12. Eleven patients were included, with a mean time from diagnosis of folliculitis decalvans to the introduction of infliximab (n = 9) or adalimumab (n = 2) of 8.55 ± 1.26 years. Nine patients had failed on at least 2 lines of systemic therapies before starting anti-tumour necrosis factor-α. The median IGA score at baseline was 3. At the end of follow-up, 5 patients were considered responders. Overall, the safety profile of anti-tumour necrosis factor-α was good. The results suggest that the clinical benefit of anti-tumour necrosis factor-α is obtained after at least 6 months of treatment. However, further prospective studies are needed to confirm these results.
- Published
- 2023
- Full Text
- View/download PDF
20. Eosinophilic pustule smear in the diagnosis of pediatric post-transplant eosinophilic folliculitis.
- Author
-
Pupa L, Blessing MM, and Hunt R
- Subjects
- Humans, Child, Blister, Folliculitis diagnosis, Folliculitis etiology, Folliculitis drug therapy, Skin Diseases, Vesiculobullous diagnosis, Skin Diseases, Vesiculobullous etiology, Skin Diseases, Vesiculobullous drug therapy, Eosinophilia diagnosis, Eosinophilia etiology, Eosinophilia drug therapy
- Abstract
Hematologic-associated eosinophilic pustular folliculitis is a subtype of eosinophilic pustular folliculitis (EPF) which develops in patients with underlying hematological malignancies after treatment with chemotherapy, bone marrow transplant (BMT), or stem cell transplant (SCT). Few cases of hematological-associated EPF have been reported in pediatric patients. Skin biopsy is considered the gold standard for diagnosis. We describe a case in which Wright staining of a pustule smear for eosinophils provided data to rapidly support a clinical diagnosis of hematologic-associated EPF., (© 2022 Wiley Periodicals LLC.)
- Published
- 2023
- Full Text
- View/download PDF
21. Topical steroid-induced prurigo-like folliculitis in children: a case series of 10 patients.
- Author
-
Shiraishi K, Tohyama M, and Sayama K
- Subjects
- Humans, Child, Steroids therapeutic use, Administration, Topical, Prurigo chemically induced, Prurigo drug therapy, Folliculitis chemically induced, Folliculitis drug therapy
- Published
- 2023
- Full Text
- View/download PDF
22. Turpentine Ointment for the Treatment of Folliculitis: An Open, Prospective, Randomized, Placebo- and Comparator-Controlled Multicenter Trial.
- Author
-
Görne RC, Günnewich N, Huber H, Wallmen B, and Zimmermann C
- Subjects
- Humans, Ointments, Prospective Studies, Skin, Treatment Outcome, Double-Blind Method, Turpentine, Folliculitis drug therapy
- Abstract
Introduction: Folliculitis is a painful infection and inflammation of the hair follicles, mostly caused by bacterial, fungal, or, more rarely, viral infections. Turpentine derivatives have been used traditionally to treat various skin infections and could thus also be effective in treating folliculitis. We carried out an open, prospective, randomized, placebo- and comparator-controlled multicenter trial to evaluate the efficacy and safety of an ointment containing pine turpentine oil, larch turpentine, and eucalyptus oil in the treatment of acute folliculitis., Methods: Seventy outpatients with acute folliculitis were treated with the turpentine ointment, a comparator (povidone iodine solution), or a placebo (Vaseline) for 7 days. Photographs of the affected skin areas were taken by the physicians at four visits and by the patients on a daily basis. Photographs were evaluated by blinded observers. Primary efficacy endpoint was the change in total hair follicle lesion counts. Secondary endpoints included the evolution of the lesion counts in the course of the study, responder rate (improvement of follicle lesions by at least one count), and the patient's global assessment. Safety endpoints were the tolerability of the treatments and adverse event recording., Results: A decrease of follicle lesions counts was detected for both active treatments but not for placebo, but the differences among groups were not statistically significant. As for the secondary endpoints, the ointment showed statistically significant superiority over placebo for the evolution of the lesions during the course of the study (p = 0.017), the responder rate (p = 0.032), and the subjective efficacy assessment by patients (p = 0.029). All treatments were equally well tolerated, with a similar number of treatment-emergent adverse events., Conclusion: The turpentine ointment is an effective and safe option for the treatment of folliculitis., (© 2023 The Author(s). Published by S. Karger AG, Basel.)
- Published
- 2023
- Full Text
- View/download PDF
23. Unilateral rosacea, unilateral demodicidosis, unitaleral Demodex sp. folliculitis: Three names for the same disease.
- Author
-
Veraldi S, Pisapia A, Nazzaro G, and Boneschi V
- Subjects
- Humans, Rosacea diagnosis, Mite Infestations diagnosis, Folliculitis diagnosis, Folliculitis drug therapy
- Published
- 2023
- Full Text
- View/download PDF
24. Eosinophilic pustular folliculitis due to naltrexone: A case report.
- Author
-
Smith SS, Cernaro N, and Tonti E
- Subjects
- Female, Humans, Young Adult, Adult, Naltrexone adverse effects, Narcotic Antagonists adverse effects, Folliculitis chemically induced, Folliculitis drug therapy, Opioid-Related Disorders drug therapy
- Abstract
Background: The effectiveness of naltrexone in treating both alcohol and opioid use disorders is unique when compared with other agents used for substance use disorder (SUD). It is estimated that 2 million Americans suffer from opioid use disorder, and 14.5 million have alcohol use disorder, underscoring the need for medication-supported SUD treatment. The aims of this case report are 2-fold: (1) to underscore the importance of conducting a thorough medication history when considering a recent adverse drug reaction and(2) to report a novel cutaneous reaction to naltrexone oral tablet., Case Summary: A 20-year-old female with a medical history significant for bipolar disorder, obsessive compulsive disorder, major depression disorder, and polysubstance use disorder experienced a drug-induced cutaneous adverse reaction on 2 separate occasions, about 3 months apart. Drug-induced adverse reactions can lead to treatment modifications, resulting in differences in efficacy and undesirable adverse effects. The purpose of this case report is to introduce naltrexone-induced skin reactions and emphasize the importance of a careful medication history when determining which medication is related to an adverse reaction., Practice Implications: Naltrexone will continue to be used to manage cravings related to SUD. This case brings awareness to severe cutaneous adverse reactions associated with enteral naltrexone. Monitoring upon initiation for any adverse effects should be part of a holistic treatment plan. In addition to conducting a complete and thorough medication history, adverse drug reactions can be correctly attributed to the offending agent and prevent future adverse reactions., (Copyright © 2022 American Pharmacists Association®. Published by Elsevier Inc. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
25. Drug Survival of Oral Retinoids in Hidradenitis Suppurativa: A Real-Life Cohort Study.
- Author
-
Bouwman K, Aarts P, Dudink K, Hao J, Alizadeh BZ, Prens LM, Vossen ARJV, van Straalen KR, van der Zee HH, and Horváth B
- Subjects
- Acitretin therapeutic use, Cicatrix drug therapy, Cohort Studies, Humans, Isotretinoin therapeutic use, Retinoids therapeutic use, Retrospective Studies, Acne Vulgaris drug therapy, Folliculitis complications, Folliculitis drug therapy, Hidradenitis Suppurativa complications, Hidradenitis Suppurativa drug therapy
- Abstract
Introduction: Cohort studies on the use of retinoids for hidradenitis suppurativa (HS) have yielded contradicting results. As the clinical presentation of HS is heterogeneous, with different predilection sites and hallmark features, it can be hypothesized that HS phenotypes are associated with the effectiveness of specific retinoid treatments., Objectives: The aim of this study was to evaluate the drug survival of oral retinoids in the treatment of HS and to establish predictors for longer treatment duration., Methods: A retrospective, dual-center study was conducted in the Netherlands in adult HS patients treated with oral retinoids between 2011 and 2021. Drug survival analyses were performed through Kaplan-Meier survival curves. Additionally, Cox regression models were used to determine predictors for a longer drug survival., Results: In total, 102 patients were included. Overall drug survival of (low-dose) isotretinoin (n = 66) at 12 and 24 months was 44.2% and 15.5%, respectively. Termination of treatment was mostly due to ineffectiveness (26%). Presence of widespread comedones (p = 0.03) and the use of concomitant systemic medication (p = 0.04) were associated with a prolonged treatment duration. For acitretin (n = 36), the overall drug survival was 42.0% at 12 months and 37.4% at 24 months, and was also predominantly determined by ineffectiveness (28%). Interestingly, the scarring folliculitis phenotype (p < 0.05) was associated with prolonged drug survival time for acitretin treatment relative to the regular phenotype., Conclusion: Comparable drug survival rates at 12 months for isotretinoin and acitretin were found. HS patients with widespread comedones and the scarring folliculitis phenotype could benefit from treatment with isotretinoin or acitretin, respectively., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
26. Therapeutic options for perifolliculitis capitis abscedens et suffodens: A review.
- Author
-
Wu Q, Bu W, Zhang Q, and Fang F
- Subjects
- Cellulitis, Humans, Folliculitis diagnosis, Folliculitis drug therapy, Scalp Dermatoses diagnosis, Scalp Dermatoses drug therapy, Skin Diseases, Genetic diagnosis, Skin Diseases, Genetic therapy
- Abstract
Perifolliculitis capitis abscedens et suffodiens (PCAS) is a chronic skin inflammatory disease characterized by relapsing folliculitis and painful, fluctuant abscesses, sinus tracts, and scars. The treatment of PCAS is challenging and clinical practice varies a lot, and how to choose the best treatment for PCAS is a real problem for clinicians. We reviewed articles providing treatment options for patients with PCAS in different databases. Dermatologists may find this review helpful to meet the challenges of PCAS management, but there is still a lack of authoritative guidelines. In the future, more robust randomized control trials are needed to determine the best treatment for PCAS., (© 2022 Wiley Periodicals LLC.)
- Published
- 2022
- Full Text
- View/download PDF
27. Refractory folliculitis decalvans treated with biologics: Case series in 4 situations.
- Author
-
Lobato-Berezo A and Pujol RM
- Subjects
- Alopecia therapy, Humans, Biological Products adverse effects, Folliculitis diagnosis, Folliculitis drug therapy
- Published
- 2022
- Full Text
- View/download PDF
28. Necrotizing Infundibular Crystalline Folliculitis-A Case Report of a Rare Entity and Review of the Literature.
- Author
-
Wiedemeyer K, Brenn T, and Naert K
- Subjects
- Adult, Back pathology, Humans, Male, Middle Aged, Exanthema, Folliculitis drug therapy, Folliculitis pathology
- Abstract
Abstract: Necrotizing infundibular crystalline folliculitis (NICF) is a rare distinct entity that was introduced in 1999. It typically presents with numerous eruptive waxy papules on the forehead and/or the upper back in adults in their fifth to seventh decade of life. The pathogenesis is unknown to date, but yeast and bacterial infection of the follicular ostia seems to contribute to the development. More recently, NICF has occasionally been observed as a side effect of targeted antitumoral therapy. Histopathologically, NICF is characterized by dilated follicular ostia filled with pale filamentous and birefringent material enclosed by parakeratotic columns of the epidermis and accompanied by a mild superficial inflammatory infiltrate of the dermis. This case report is about a 58-year-old male patient presenting with multiple eruptive keratotic papules on his forehead. Histopathology revealed all classic features of NICF. The case represents a classic example of NICF and is compared with previously published cases that are comprehensively summarized in this article., Competing Interests: The authors declare no conflicts of interest., (Copyright © 2022 Written work prepared by employees of the Federal Government as part of their official duties is, under the U.S. Copyright Act, a “work of the United States Government” for which copyright protection under Title 17 of the United States Code is not available. As such, copyright does not extend to the contributions of employees of the Federal Government.)
- Published
- 2022
- Full Text
- View/download PDF
29. Malassezia Folliculitis following Triple Therapy for Cystic Fibrosis.
- Author
-
Li Pomi F, Di Bartolomeo L, Vaccaro M, Lentini M, Cristadoro S, Lucanto MC, Lombardo M, Costa S, and Borgia F
- Subjects
- Aminophenols, Cystic Fibrosis Transmembrane Conductance Regulator genetics, Cystic Fibrosis Transmembrane Conductance Regulator pharmacology, Cystic Fibrosis Transmembrane Conductance Regulator therapeutic use, Drug Combinations, Female, Humans, Mutation, Quinolones, Cystic Fibrosis complications, Cystic Fibrosis diagnosis, Cystic Fibrosis drug therapy, Folliculitis chemically induced, Folliculitis drug therapy, Malassezia
- Abstract
Triple-combination therapy with elexacaftor, tezacaftor and ivacaftor has been recently approved for cystic fibrosis patients with at least one F508 del mutation in the transmembrane conductance regulator of the cystic fibrosis gene. Among the adverse events of elexacaftor, tezacaftor and ivacaftor, the cutaneous ones have been rarely reported, mainly dealing with urticarial-like rashes. On this topic, we report two cases of Malassezia folliculitis following triple therapy administration in two young females. In the first patient, a papulopustular rush appeared before the folliculitis while in the second patient it was not preceded by other skin manifestations. The diagnosis was confirmed both by dermoscopy and histology. The prompt response to systemic antimycotic drugs provided further evidence for the causative role of Malassezia, requiring no discontinuation of cystic fibrosis therapy. We could hypothesize that the triple regimen treatment may induce changes in the skin microbiome, potentially able to favor colonization and proliferation of Malassezia species. Physicians should be aware of such associations to allow prompt diagnosis and early interventions, avoiding useless drug removal.
- Published
- 2022
- Full Text
- View/download PDF
30. Refractory folliculitis decalvans treated with adalimumab: A case series of 23 patients.
- Author
-
Iorizzo M, Starace M, Vano-Galvan S, Piraccini BM, Reygagne P, Rudnicka L, Silyuk T, Sinclair R, and Tosti A
- Subjects
- Adalimumab therapeutic use, Humans, Alopecia therapy, Folliculitis drug therapy
- Abstract
Competing Interests: Conflicts of interest None disclosed.
- Published
- 2022
- Full Text
- View/download PDF
31. Topical dapsone for folliculitis decalvans: A retrospective cohort study.
- Author
-
Melián-Olivera A, Burgos-Blasco P, Selda-Enríquez G, Suárez-Valle A, Miguel-Gómez L, Vañó-Galván S, and Saceda-Corralo D
- Subjects
- Alopecia, Humans, Retrospective Studies, Dapsone therapeutic use, Folliculitis drug therapy
- Abstract
Competing Interests: Conflicts of interest None disclosed.
- Published
- 2022
- Full Text
- View/download PDF
32. A case of eosinophilic pustular folliculitis successfully treated with adalimumab.
- Author
-
Ramondetta A, Giuffrida G, Di Vincenzo S, and De Pasquale R
- Subjects
- Adalimumab therapeutic use, Humans, Eosinophilia diagnosis, Eosinophilia drug therapy, Folliculitis diagnosis, Folliculitis drug therapy, Skin Diseases, Vesiculobullous diagnosis, Skin Diseases, Vesiculobullous drug therapy
- Published
- 2022
- Full Text
- View/download PDF
33. Treatment of eosinophilic pustular folliculitis with low-dose isotretinoin.
- Author
-
Gallo G, Conti L, Quaglino P, and Ribero S
- Subjects
- Humans, Isotretinoin therapeutic use, Eosinophilia drug therapy, Folliculitis diagnosis, Folliculitis drug therapy, Skin Diseases, Vesiculobullous diagnosis, Skin Diseases, Vesiculobullous drug therapy
- Published
- 2022
- Full Text
- View/download PDF
34. Common condition with uncommon cause: fungal folliculitis in immunosuppressed patient with Blau syndrome.
- Author
-
Ebadian M, Barbieri A, and Shpadaruk V
- Subjects
- Arthritis, Humans, Folliculitis diagnosis, Folliculitis drug therapy, Folliculitis microbiology, Sarcoidosis complications, Sarcoidosis diagnosis, Sarcoidosis drug therapy, Synovitis, Uveitis diagnosis, Uveitis drug therapy
- Abstract
We present a case of a patient with a history of Blau syndrome, who presented with acute onset of widespread florid painful folliculitis rash, which was resistant to the treatment with multiple courses of antibiotics in the community. Despite of the negative skin swab and negative periodic acid-schiff (PAS)stain on the skin biopsy, clinical diagnosis was fungal folliculitis and patient responded well to the course of itraconazole., Competing Interests: Competing interests: None declared., (© BMJ Publishing Group Limited 2022. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2022
- Full Text
- View/download PDF
35. Hostage to history - questioning the duration of systemic antimicrobial therapy for the treatment of canine superficial bacterial folliculitis.
- Author
-
Sousa CA, Chatfield J, File TM, Koch SN, Leu DB, Loeffler A, Loft KE, Souza C, and Weese JS
- Subjects
- Dogs, Animals, Humans, Anti-Bacterial Agents therapeutic use, Dog Diseases drug therapy, Folliculitis drug therapy, Folliculitis microbiology, Folliculitis veterinary, Anti-Infective Agents therapeutic use, Prisoners
- Abstract
Current guidelines for the use of systemic antimicrobials for the treatment of superficial bacterial folliculitis in dogs include the recommendation that the disease be treated for a minimum of 3 weeks and for at least 1 week beyond clinical resolution. With increasing antimicrobial resistance being noted for bacteria involved in this condition, as well as the increased use of evidence-based medicine, this dogma needs to be reevaluated.
- Published
- 2022
- Full Text
- View/download PDF
36. Successful treatment of folliculitis decalvans with baricitinib: A case series.
- Author
-
Moussa A, Asfour L, Eisman S, Bhoyrul B, and Sinclair R
- Subjects
- Alopecia drug therapy, Humans, Purines therapeutic use, Pyrazoles, Sulfonamides, Azetidines therapeutic use, Folliculitis drug therapy
- Published
- 2022
- Full Text
- View/download PDF
37. Infantile Eosinophilic Pustular Folliculitis: A Case Report.
- Author
-
Saylam Kurtipek G, Zekey E, Tuncez Akyurek F, Demirbas A, and Harmankaya İ
- Subjects
- Hair Follicle pathology, Humans, Infant, Male, Eosinophilia diagnosis, Eosinophilia drug therapy, Eosinophilia pathology, Folliculitis diagnosis, Folliculitis drug therapy, Skin Diseases, Vesiculobullous diagnosis, Skin Diseases, Vesiculobullous drug therapy, Skin Diseases, Vesiculobullous pathology
- Abstract
Background: Infantile eosinophilic pustular folliculitis (I-EPF) is a rare disease characterized by pruritic vesicles and sterile pustules on the erythematous surface of the scalp and facial localization, usually seen in the neonatal period. It is essential to show the presence of dense eosinophils in the diagnosis of pustules. Histopathological examination of the hair follicles by eosinophils infiltration is determined., Aim: Here, we reported a 5-month-old baby boy diagnosed infantile eosinophilic pustular folliculitis., Patient: A 5-month-old baby boy was consulted to our polyclinic by his family because of pustules on the scalp, face, and neck developing in two week after birth. In dermatological examination, the pustular lesions of 1-2 mm in diameter on the scalp, face, and neck on an erythematous background were determined., Results: There was no growth in the culture taken from the pustule. In the laboratory tests of the patient; upon detection of eosinophilia in the hemogram. The eosinophil count at the patient's first admission was 1.48 K/μl. (0.05 0.50). Eosinophil count was 0.02 K/μl after treatment. It was decreased. The patient was evaluated for other pustular dermatoses. In the differential diagnosis of the patient; causing bacterial/non-bacterial pustulosis were included. Bacterial culture was negative., Conclusion: Eosinophilic folliculitis defines as a group of papulopustular diseases with unknown etiology characterized histologically by eosinophilic infiltrates. First, Ofuji reported a female patient with recurrent follicular pustules and peripheral eosinophilia as a variant of folliculitis in 1965. Its etiopathogenesis is not clearly known. In the differential diagnosis of EPF includes the other pustular lesions of the newborn such as erythematoxicum neonatarum, transient neonatal pustular dermatosis, infantile acropustulosis, scabies, dermatophytosis, and langerhans cell histiocytosis. Treatment options includes topical corticosteroids and calcineurin inhibitors, antihistamines, systemic antibacterial and anti-inflammatory agents, and dapson., (© 2021 Wiley Periodicals LLC.)
- Published
- 2022
- Full Text
- View/download PDF
38. Therapy-refractory folliculitis decalvans treated with certolizumab pegol.
- Author
-
Hoy M and Böhm M
- Subjects
- Humans, Polyethylene Glycols, Alopecia, Certolizumab Pegol therapeutic use, Folliculitis drug therapy
- Published
- 2022
- Full Text
- View/download PDF
39. Paradoxical Perforating Folliculitis in a Newly Transplanted Kidney Recipient: Case Study.
- Author
-
Nonkala OR, Haffejee MI, van der Walt M, Moodley A, Hariparshad SP, and Assounga AGH
- Subjects
- Humans, Kidney pathology, Male, Tacrolimus adverse effects, Treatment Outcome, Folliculitis diagnosis, Folliculitis drug therapy, Folliculitis etiology, Kidney Transplantation adverse effects
- Abstract
We report on a rare case of perforating folliculitis with a paradoxical presentation. An 18-year-old patient with end-stage kidney failure was undergoing continuous ambulatory peritoneal dialysis following 1 year of hemodialysis treatment. While being treated with continuous ambulatory peritoneal dialysis, he developed an itchy papular eruption on an erythematous base over his face and chest, which was diagnosed as chicken pox and treatedwith acyclovir.He also underwent successful deceased donor kidney transplant 1 year later. On day 10 posttransplant, he presented with a papular eruption over the chest, face, and forearms. A skin biopsy revealed a perforating folliculitis lesion. He was treated with prednisone and tacrolimus, as part of the kidney transplant treatment. The skin lesions resolved progressively. His urea, creatinine, and electrolyte levels remained normal and on an ever-improving trend at each visit. By 4 months posttransplant, the skin lesions had resolved almost completely.
- Published
- 2022
- Full Text
- View/download PDF
40. Adalimumab for interleukin-1β-mediated chronic non-scarring scalp folliculitis: Case report and literature review.
- Author
-
Soglia S, Maione V, Bugatti M, Vermi W, Calzavara-Pinton P, and Venturini M
- Subjects
- Adalimumab therapeutic use, Humans, Interleukin-1beta, Scalp, Folliculitis diagnosis, Folliculitis drug therapy, Scalp Dermatoses diagnosis, Scalp Dermatoses drug therapy
- Abstract
Chronic non-scarring scalp folliculitis is a little-known entity included within the spectrum of scalp folliculitis, a group of diseases sharing clinical features but with heterogeneity in terms of residual scarring (always absent in chronic non-scarring scalp folliculitis), microbiology, and response to antibiotics. Chronic non-scarring scalp folliculitis is most likely an inflammatory disease within the group of neutrophilic dermatoses. The recognition of the inflammatory nature of this disease may pave the way for the use of new therapies, directly targeting pathogenic molecules. Herein, we report the first case of chronic non-scarring scalp folliculitis treated by adalimumab., (© 2021 Japanese Dermatological Association.)
- Published
- 2022
- Full Text
- View/download PDF
41. Atypical folliculitis caused by Malassezia spp. in immunosuppressed patients.
- Author
-
Marín-Hernández E, Mejía-Mancera CG, Quijada-Henderson MA, and Valero-Gómez A
- Subjects
- Adolescent, Biopsy, Humans, Male, Dermatomycoses diagnosis, Dermatomycoses drug therapy, Folliculitis diagnosis, Folliculitis drug therapy, Folliculitis pathology, Malassezia, Neutropenia
- Abstract
Background: Folliculitis due to Malassezia spp. (MF), caused mainly by Malassezia furfur, is clinically characterized by an acneiform eruption expressing follicular papules and pustules, predominantly on the trunk. Diagnosis of MF requires confirmation of the presence of yeasts in the hair follicle. The treatment of choice is topical or oral with azoles. We report two cases of folliculitis due to Malassezia spp. of atypical distribution in immunosuppressed patients., Case Reports: Case 1. We describe a 14-year-old male patient diagnosed with chondroid osteosarcoma who required surgical treatment and chemotherapy. He was hospitalized for fever and neutropenia, presenting a rash of papulopustular lesions on the upper and lower extremities and neck. Direct examination and biopsy were performed to conclude the diagnosis of disseminated atypical Malassezia spp. folliculitis. Case 2. We describe a 16-year-old male patient diagnosed with synovial sarcoma, treated with surgical resection and chemotherapy. During hospitalization due to fever and neutropenia, he presented with disseminated dermatosis of the head, trunk, and upper extremities, showing multiple follicular papules and pustules with erythematous base; on the trunk, there were few lesions. In the supraciliary region, he showed erythema and furfuraceous desquamation. Direct examination of a follicle showed thick-walled round yeasts compatible with MF., Conclusions: MF is a frequent entity but of low diagnostic suspicion. Immunosuppressed patients may manifest atypical clinical characteristics in non-seborrheic areas, implying diagnostic difficulty. Biopsy and direct examination are essential to corroborate the etiology in patients with immunosuppression or with a non-classical presentation., (Copyright: © 2022 Permanyer.)
- Published
- 2022
- Full Text
- View/download PDF
42. Disseminate and Recurrent Infundibulofolliculitis: An Under-Recognized Yet Treatable Entity.
- Author
-
Ma BC, Sahni VN, Sahni DR, and Secrest AM
- Subjects
- Humans, Recurrence, Retinoids, Young Adult, Exanthema, Folliculitis diagnosis, Folliculitis drug therapy, Neoplasms
- Abstract
Disseminate and recurrent infundibulofolliculitis (DRIF) is a pruritic papular eruption that predominantly affects young adults with Fitzpatrick skin types 4-6. Due to DRIF’s rarity and under-recognition, no standardized treatment guidelines exist. However, several oral agents have been used, including vitamin A, antibiotics, and retinoids. Topical agents, such as calcineurin inhibitors and mid-potency steroids, can also be efficacious. This brief communication summarizes treatments for DRIF in the published literature. J Drugs Dermatol. 2021;20(12):1353-1354. doi:10.36849/JDD.6173.
- Published
- 2021
- Full Text
- View/download PDF
43. An update on pityrosporum folliculitis in Singapore from a single tertiary care dermatological centre.
- Author
-
Yong AM, Tan SY, and Tan CL
- Subjects
- Adult, Female, Humans, Male, Singapore epidemiology, Tertiary Healthcare, Young Adult, Dermatomycoses diagnosis, Dermatomycoses drug therapy, Dermatomycoses epidemiology, Folliculitis diagnosis, Folliculitis drug therapy, Folliculitis epidemiology, Malassezia
- Abstract
Introduction: Pityrosporum folliculitis (PF) is a common skin condition that can be easily misdiagnosed, especially by non-dermatologists. While the initial diagnosis is often made clinically, skin microscopy may help to confirm the same. However, there is scant literature regarding the clinical epidemiology of PF. To our knowledge, in Singapore, only one prior epidemiological study was performed in 1987. Through the present study, we aimed to provide an update regarding the epidemiology, diagnosis and treatment of patients with PF in Singapore., Methods: We performed a retrospective review of patients with clinical presentations compatible with PF who presented to the dermatology clinic at the National University Hospital, Singapore, between 1 January 2011 and 31 December 2015. The medical records of patients identified as having clinical presentations that resembled PF were reviewed via written and electronic databases. Information regarding the demographics and clinical presentation of the patients was collected., Results: Of the 375 patients identified, 214 (57.1%) were confirmed as having PF based on Gram-stain microscopy. Most (35.0%) of these 214 patients were aged between 21 and 30 years, with a male-to-female ratio of 3:1. The lesions predominantly occurred on the trunk and the back. The majority of patients presented with symptoms that lasted more than one month. 128 (59.8%) patients received oral antifungal treatment, whereas 82 (38.3%) patients were treated with topical antifungal treatment alone., Conclusion: A typical Singapore patient with PF is a young man aged 21-30 years, with erythematous follicular papules or pustules over the trunk and the back., (Copyright: © Singapore Medical Association.)
- Published
- 2021
- Full Text
- View/download PDF
44. Photodynamic therapy should be considered for the treatment of folliculitis decalvans.
- Author
-
Yang L, Chen J, Tong X, Gao L, Ding S, and Guo A
- Subjects
- Alopecia, Humans, Photosensitizing Agents therapeutic use, Retrospective Studies, Folliculitis drug therapy, Photochemotherapy methods
- Abstract
Background: Different therapies such as clindamycin, rifampicin, isotretinoin, or corticosteroids have been used for folliculitis decalvans with poor results. Recently, PDT has been used for treating folliculitis decalvans more frequently. However, the efficacy of PDT for treating folliculitis decalvans is lacking consensus. In this study, we conducted a retrospective analysis to evaluated the status of PDT for the treatment of folliculitis decalvans., Methods: 13 cases of folliculitis decalvans patients were treated with ALA-PDT. The treatment totals 3 times, and the interval between each treatment was 10-14 days. A follow-up was conducted at 12 months after the last treatment. The condition was graded according to the following evaluation criteria: recovery, significant improvement, moderate improvement, ineffective., Results: A total of 7 cases improved significantly, and 6 cases improved moderately followed the first treatment. After the second treatment, 10 cases showed significant improvement, and 2 cases responded poorer than the first treatment. After the third treatment, 4 cases recovered, 7 cases improved significantly, and 2 case moderately improved. At the 12-months follow-up, 9 out of 13 patients were well controlled and with no recurrence. The other 4 patients relapsed., Conclusion: In summary, photodynamic therapy shows overall favorable effect on folliculitis decalvans and should be considered as a method for the treatment of folliculitis decalvans., (Copyright © 2021 Elsevier B.V. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
45. Common Cutaneous Infections: Patient Presentation, Clinical Course, and Treatment Options.
- Author
-
Preda-Naumescu A, Elewski B, and Mayo TT
- Subjects
- Adolescent, Adult, Bacterial Infections complications, Bacterial Infections microbiology, Child, Child, Preschool, Ecthyma diagnosis, Ecthyma drug therapy, Erysipelas diagnosis, Erysipelas drug therapy, Erythema Multiforme diagnosis, Erythema Multiforme drug therapy, Fasciitis, Necrotizing diagnosis, Fasciitis, Necrotizing drug therapy, Folliculitis diagnosis, Folliculitis drug therapy, Herpes Genitalis diagnosis, Herpes Genitalis drug therapy, Herpes Labialis diagnosis, Herpes Labialis drug therapy, Herpesviridae Infections complications, Herpesviridae Infections virology, Humans, Impetigo diagnosis, Impetigo drug therapy, Kaposi Varicelliform Eruption diagnosis, Kaposi Varicelliform Eruption drug therapy, Middle Aged, Mycoses complications, Mycoses microbiology, Onychomycosis diagnosis, Onychomycosis drug therapy, Practice Patterns, Physicians' statistics & numerical data, Skin Diseases, Infectious microbiology, Skin Diseases, Infectious virology, Tinea Capitis diagnosis, Tinea Capitis drug therapy, Young Adult, Bacterial Infections pathology, Herpesviridae Infections pathology, Mycoses pathology, Skin Diseases, Infectious drug therapy, Skin Diseases, Infectious pathology
- Abstract
This evidence-based review highlights cutaneous infections of bacterial, viral, and fungal origin that are frequently encountered by clinicians in all fields of practice. With a focus on treatment options and management, the scope of this article is to serve as a reference for physicians, regardless of field of specialty, as they encounter these pathogens in clinical practice., Competing Interests: Disclosure No author has a financial or proprietary interest in any material or method mentioned., (Copyright © 2021 Elsevier Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
46. Treatment of eosinophilic pustular folliculitis with benralizumab in a 13-year-old girl.
- Author
-
Bürgler C, Guillet C, Kolm I, Theiler M, Schmid-Grendelmeier P, Kroiss S, and Weibel L
- Subjects
- Adolescent, Female, Humans, Antibodies, Monoclonal, Humanized therapeutic use, Eosinophilia drug therapy, Folliculitis drug therapy, Skin Diseases, Vesiculobullous drug therapy
- Published
- 2021
- Full Text
- View/download PDF
47. Effective treatment of folliculitis decalvans with cyclosporin: A case series.
- Author
-
Jerjen R, Meah N, Trindade de Carvalho L, Wall D, Gunatheesan S, and Sinclair R
- Subjects
- Adult, Cyclosporine therapeutic use, Dermatologic Agents pharmacology, Dermatologic Agents therapeutic use, Female, Folliculitis physiopathology, Humans, Male, Middle Aged, Treatment Outcome, Cyclosporine pharmacology, Folliculitis drug therapy
- Published
- 2021
- Full Text
- View/download PDF
48. A Case of Eosinophilic Pustular Folliculitis Associated With Herpes Zoster.
- Author
-
Lee JH, Lee SK, Kim JH, Kim HY, Kim MS, and Lee UH
- Subjects
- Eosinophilia drug therapy, Eosinophilia immunology, Eosinophilia virology, Female, Folliculitis drug therapy, Folliculitis immunology, Folliculitis virology, Herpes Zoster immunology, Herpes Zoster virology, Herpesvirus 3, Human immunology, Histamine Antagonists therapeutic use, Host-Pathogen Interactions, Humans, Skin drug effects, Skin immunology, Skin virology, Skin Diseases, Vesiculobullous drug therapy, Skin Diseases, Vesiculobullous immunology, Skin Diseases, Vesiculobullous virology, Steroids therapeutic use, Th2 Cells immunology, Treatment Outcome, Young Adult, Eosinophilia pathology, Folliculitis pathology, Herpes Zoster pathology, Herpesvirus 3, Human pathogenicity, Skin pathology, Skin Diseases, Vesiculobullous pathology
- Abstract
Abstract: Patients with eosinophilic pustular folliculitis (EPF), a sterile eosinophilic infiltration of hair follicles, often present with papulopustules that tend to form annular plaques. Histopathologic examination revealed eosinophilic infiltration around the pilosebaceous units and eosinophilic microabscess formation. Although the pathogenesis of EPF is unknown, T-helper type 2 immune responses were suggested to be important based on their stimulating effect on the sebaceous glands. Here, we report the first case of EPF associated with herpes zoster, indicating that herpes zoster and EPF are correlated with T-helper type 2 immune responses., Competing Interests: The authors declare no conflicts of interest., (Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
49. Skin manifestations of Pseudomonas aeruginosa infections.
- Author
-
Spernovasilis N, Psichogiou M, and Poulakou G
- Subjects
- Animals, Anti-Bacterial Agents administration & dosage, Folliculitis drug therapy, Folliculitis microbiology, Humans, Pseudomonas Infections drug therapy, Pseudomonas aeruginosa drug effects, Skin Diseases, Bacterial drug therapy, Pseudomonas Infections microbiology, Pseudomonas aeruginosa physiology, Skin Diseases, Bacterial microbiology
- Abstract
Purpose of Review: Pseudomonas aeruginosa is an opportunistic pathogen with considerable morbidity and mortality, particularly in vulnerable hosts. Skin manifestations are common, either representing local inoculation or secondary skin seeding following bloodstream infections. As patients with various predisposing conditions are expanding, we sought to review the most recent published evidence regarding epidemiology, risk factors and diagnosis of skin manifestations of P. aeruginosa., Recent Findings: New data exist on epidemiology and diagnosis of skin infections; systemic infections are impacted by multidrug-resistance issues and host immune status., Summary: Green nail syndrome, toe web infection, hot tub folliculitis, hot hand-foot infection and external otitis are the most common infections originating from the skin per se. Local treatments are the cornerstone and prognosis is favorable in immunocompetent hosts. Ecthyma gangrenosum and P. aeruginosa subcutaneous nodules are usually associated with bloodstream infections and occur primarily in immunocompromised hosts. Necrotizing skin and soft tissue infections occur in diabetic, alcoholic and immunocompromised patients; management requires a multidisciplinary team with surgical approach. Burn wound infections may also be challenging, requiring a specialized team. In all the four latter types of P. aeruginosa skin infections portending significant morbidity and mortality, systemic antibiotics are an integral part of the treatment., (Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
50. Necrotizing infundibular (ostial) crystalline folliculitis.
- Author
-
Roux GA and Fraitag S
- Subjects
- Adult, Humans, Folliculitis diagnosis, Folliculitis drug therapy, Malassezia
- Abstract
Necrotizing infundibular crystalline folliculitis is a rare condition characterized by folliculocentric waxy papules in the seborrheic areas of adult patients, with intrafollicular filamentous birefringent crystalline deposits as the histopathologic clue. Although the real pathogenesis of necrotizing infundibular crystalline folliculitis remains unclear, the intrafollicular material seems to be derived from an interaction between such superficial microorganisms as gram-positive bacteria (Propionibacterium acnes, Staphylococcus spp), Malassezia yeasts, and sebaceous lipids. Topical or systemic antiacne agents or antimycotics appear to be effective therapy., (Copyright © 2020 Elsevier Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.